Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PRO1160 in metastatic renal cell carcinoma, recurrent/metastatic nasopharyngeal carcinoma, or advanced non-Hodgkin lymphoma
CTR20231732Phase 2Terminated
- Sponsor
- ProfoundBio
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PRO1160 in renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), non-Hodgkin lymphoma (NHL), sponsored by ProfoundBio. Started Aug 2023; status: terminated.
02
Drugs
PRO1160
03
Conditions
renal cell carcinoma (RCC)nasopharyngeal carcinoma (NPC)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20231732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231732.